Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Mode of Action

 

Therapeutic Indications

Dosing

References
 

  1. CRESEMBA Summary of Product Characteristics. 2021.
  2. VFEND Summary of Product Characteristics. 2021.
  3. Noxafil Summary of Product Characteristics. 2021.
  4. Sporanox Summary of Product Characteristics. 2020.
  5. Miceli MH and Kauffman CA. Clin Infect Dis 2015;61(10):1558–1565.
  6. Falci DR and Pasqualotto AC. Infect Drug Resist 2013;6:163-174.
  7. Rybak JM et al. Pharmacotherapy 2015;35(11):1037–1051.
  8. Arendrup MC et al. Antimicrob Agents Chemother 2015;59(12):7735–7742.
  9. Guinea J et al. Antimicrob Agents Chemother 2008;52(4):1396–1400.
  10. Sabatelli F et al. Antimicrob Agents Chemother 2006;50(6):2009–2015.

 

Prescribing information ​​​

Cresemba® (isavuconazole)
Cresemba® (isavuconazole) 200mg powder for concentrate for solution for infusion ​​​

VFend® (voriconazole)
VFend® (voriconazole) 200mg powder for solution for infusion

 

PP-CRB-IRL-0127   Date of Preparation: October 2021    Legal Category: S1A